Daniel James Hodson

37PUBLICATIONS
331CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Jul 22, 2026
CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma.

|May 12, 2026
Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma.

|Apr 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

|Mar 19, 2026
Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy.

Joanna A Krupka, Alimu Dayimu, Daniel J Hodson

|Jan 20, 2026
DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival.

Giorgia Chiodin, Dylan James Tatterton, Philip J Rock

|Dec 22, 2025
Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Joanna A Krupka, Ilias Moutsopoulos, Natasha H Cutmore

Pageof 7

Frequent Collaborators

5 joint publications

Joanna A Krupka

4 joint publications

David W Scott

3 joint publications

Daniel Leonganmornlert

3 joint publications

Krishnaa Mahbubani